Among biologics, dupilumab and tezepelumab target IL-4Rα and TSLP, respectively, and IL-4 and TSLP acted on ILC2s directly in in vivo or in vitro studies; therefore, these biologics might attenuate ILC2-mediated asthma. Here, IL4R is linked to asthma.